Dartsbio Pharmaceuticals

Dartsbio Pharmaceuticals is a clinical-stage biotechnology company focused on developing next-generation multi-specific biologics for the treatment of ophthalmic and oncology diseases. The company utilizes its proprietary Darts (Dual-Action Receptor-Targeted System) platform to engineer fusion proteins and bispecific antibodies that target multiple disease pathways simultaneously. Its lead programs, such as DSB-016 and DSB-002, aim to provide superior efficacy and longer durability compared to current standard-of-care treatments for retinal diseases like wet age-related macular degeneration. Headquartered in Guangzhou, China, Dartsbio is backed by prominent life science investors and led by an experienced team with deep expertise in protein engineering.